Nexentis unit MitoCareX deploys computational drug-discovery infrastructure on Google Cloud
NXTS•MitoCareX Bio, a wholly owned Nexentis unit, moved its computational drug-discovery infrastructure to Google Cloud Platform. The deployment aims to support scalable research computing, data governance, controlled access and workflow continuity.
1. Cloud deployment
MitoCareX Bio moved its computational drug-discovery infrastructure to Google Cloud Platform. The deployment centralizes data management, standardizes user permissions and supports flexible storage and computing as project needs change.
